Drugs Containing Excipient (Inactive Ingredient) HYDRATED SILICA

Branded drugs containing HYDRATED SILICA excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Colgate-Palmolive Company	COLGATE TOTAL WHITENING	sodium fluoride and triclosan	35000-002	HYDRATED SILICA
Colgate-Palmolive Company	COLGATE	sodium fluoride and triclosan	35000-003	HYDRATED SILICA
Colgate-Palmolive Company	COLGATE TOTAL ADVANCED FRESH PLUS WHITENING	sodium fluoride and triclosan	35000-004	HYDRATED SILICA

Generic drugs containing HYDRATED SILICA excipient

Company	Ingredient	NDC	Excipient
Accord Healthcare Inc	bupropion hydrochloride	16729-443	HYDRATED SILICA
Rebel Distributors Corp	hydrocodone bitartrate and acetaminophen	21695-273	HYDRATED SILICA
Colgate-Palmolive Company	sodium fluoride and triclosan	35000-002	HYDRATED SILICA

Hydrated Silica Excipient Market Dynamics and Financial Trajectory

Last updated: September 24, 2026

Hydrated silica is a specialty, low-volume pharmaceutical excipient used mainly as an adsorbent, flow aid, carrier, anti-caking agent, and formulation stabilizer. Its commercial outlook is positive but measured. Revenue growth depends more on higher-value pharmaceutical grades, oral-care demand, and formulation outsourcing than on broad pharmaceutical volume expansion.

The market has no reliable public reporting category for pharmaceutical-grade hydrated silica alone. Producers generally report it within larger silica, health-care, specialty materials, or engineered minerals businesses. Financial analysis therefore requires proxy indicators: pharmaceutical and oral-care demand, silica prices, energy costs, regulatory qualification, capacity utilization, and supplier mix.

What is hydrated silica and how is it used in pharmaceuticals?

Hydrated silica is amorphous silicon dioxide containing physically associated water. Commercial materials may be produced through precipitation, gel formation, or related wet-process routes. Product properties vary substantially by surface area, pore volume, particle size, moisture content, bulk density, pH, and oil-absorption capacity.

Its pharmaceutical uses include:

Use	Formulation role	Commercial relevance
Flow aid	Improves powder flow and reduces cohesion	Common in solid-dose manufacturing
Adsorbent	Converts liquids, oils, and low-melting materials into free-flowing powders	Useful for oily actives, flavors, and botanical extracts
Carrier	Distributes low-dose or liquid ingredients through a powder blend	Supports direct compression and capsule production
Anti-caking agent	Limits agglomeration during storage	Relevant to powders, granules, and premixes
Stabilizer	Supports physical stability in selected formulations	Product-specific and formulation-dependent
Abrasive	Provides cleaning action in toothpaste	A major non-pharmaceutical outlet
Chromatographic or processing aid	Supports separation and processing operations	Smaller specialty market

Hydrated silica should be distinguished from colloidal silicon dioxide, often identified as anhydrous colloidal silica, and from fumed silica. These materials can have different compendial names, manufacturing processes, particle structures, and regulatory specifications. A supplier’s “silica” portfolio may include all three categories even when only one is suitable for a particular drug product.

How large is the pharmaceutical hydrated silica market?

A defensible standalone global market size is not publicly available. Market research reports frequently aggregate precipitated silica, colloidal silica, fumed silica, hydrated silica, and industrial silica, producing figures that cannot be used as pharmaceutical-grade hydrated silica revenue.

The addressable pharmaceutical segment is structurally smaller than the food, oral-care, rubber, coatings, plastics, and animal-nutrition segments. Pharmaceutical demand has higher qualification value because customers require controlled specifications, lot traceability, change-control support, and regulatory documentation. It does not necessarily generate the highest tonnage.

The market has four economic characteristics:

1. Pharmaceutical volumes are relatively small compared with industrial silica.
2. Qualification cycles can last months or years.
3. Approved suppliers often retain business through documentation and formulation know-how.
4. Margin depends on grade differentiation rather than raw silica volume alone.

Large suppliers typically monetize hydrated silica through a portfolio model. Pharmaceutical sales may be reported with specialty minerals, health-care materials, or silica solutions rather than as a separate line item.

What is driving demand for hydrated silica excipients?

Demand is linked to solid oral dosage production, contract manufacturing, and formulation complexity.

Direct-compression and high-throughput manufacturing

Direct compression reduces processing steps and is widely used for tablets. Flowability, uniformity, and compressibility are central process requirements. Hydrated silica can improve powder handling when used at low concentrations, although its performance depends on particle morphology and interactions with the active ingredient and other excipients.

Growth in poorly soluble active ingredients

Many development-stage and commercial small molecules have low aqueous solubility. Hydrated silica can act as a carrier or adsorbent for selected liquid formulations, self-emulsifying systems, lipid-based systems, and botanical ingredients. It is not a universal solubility enhancer, but it can improve manufacturability and powder handling.

Contract development and manufacturing

CDMOs and formulation specialists often maintain multiple silica grades to address powder flow, adsorption, and stability problems. This creates demand for technical support and small-batch qualification, favoring suppliers with application laboratories and global regulatory files.

Oral-care demand

Toothpaste is a large and technically important outlet for hydrated silica and related precipitated silica products. Oral-care volumes can provide manufacturing scale and help suppliers spread fixed costs across pharmaceutical and consumer-health customers. Changes in toothpaste formulations, abrasivity requirements, and regional product preferences affect the broader silica business.

Regulatory preference for established excipients

Drug developers generally prefer excipients with established compendial status, prior human exposure, and supplier documentation. This favors incumbent grades and makes substitution difficult once a silica product is included in a regulated drug product.

Which companies supply pharmaceutical-grade hydrated silica?

The competitive field includes global specialty-materials companies and regional silica manufacturers. Product suitability must be assessed by grade, not by corporate product family.

Supplier or group	Relevant silica capability	Strategic position
Evonik Industries	AEROSIL fumed silica and related specialty silica products	Strong global technical and regulatory infrastructure
Grace	SYLOID and related porous or colloidal silica materials	Focus on pharmaceutical, nutraceutical, and formulation applications
Cabot	Fumed silica and specialty materials	Broad global manufacturing and technical base
Solvay	Precipitated silica and specialty silica products	Strong industrial and consumer-health exposure
Huber Engineered Materials	Specialty minerals and silica-related materials	North American supply and application capabilities
PQ Corporation	Silicates and specialty silica products	Broad industrial and specialty-materials footprint
Regional precipitated-silica producers	Hydrated and precipitated silica grades	Compete on price, regional supply, and customized specifications

This list includes companies with silica capabilities, not a confirmation that every listed product is a pharmaceutical-grade hydrated silica excipient. Pharmaceutical buyers typically evaluate a specific grade’s Drug Master File, compendial conformity, elemental impurities profile, microbiological controls, particle characteristics, and change-control history.

What is the FDA regulatory status of hydrated silica?

Hydrated silica does not have a single regulatory status that applies to every commercial product. FDA treatment depends on the chemical identity, intended use, specifications, exposure level, manufacturing process, and product documentation.

The relevant regulatory framework includes:

• FDA’s Inactive Ingredient Database, which provides precedent for excipient use in approved drug products.
• The United States Pharmacopeia-National Formulary, where applicable silica monographs and general chapters define quality expectations.
• 21 C.F.R. provisions addressing silicon dioxide and related food or pharmaceutical uses.
• European Pharmacopoeia and national implementation requirements for European products.
• IPEC guidelines for excipient quality systems, qualification, and change control.

FDA’s Inactive Ingredient Database is useful for identifying precedent, but an entry does not automatically establish suitability for every route, dosage form, concentration, or patient population (U.S. Food and Drug Administration, n.d.).

Hydrated silica also falls within broader regulatory expectations concerning elemental impurities, microbial quality, particle-size control, extractables, and nanomaterial characterization. Amorphous silica should not be treated as equivalent to crystalline silica for toxicological or occupational-health analysis. The manufacturing process must establish the relevant material identity.

What patents protect hydrated silica excipients?

The base excipient is generally mature and broadly off-patent. Competitive protection resides in manufacturing processes, particle engineering, surface treatment, pore structure, grade specifications, and drug-product applications.

Manufacturing and composition patents

Potentially protectable features include:

• Controlled particle-size distributions
• High-pore-volume or high-surface-area structures
• Defined moisture content
• Surface modification or functionalization
• Improved dispersibility
• Reduced dusting
• Specific impurity profiles
• Process conditions that improve batch consistency

These claims may have commercial value when they produce measurable formulation or manufacturing benefits. Broad claims to ordinary amorphous hydrated silica face substantial prior-art exposure.

Formulation and method-of-use patents

Drug-product patents may claim:

• A specific active ingredient combined with silica
• A defined silica-to-active ratio
• Improved dissolution or stability
• A liquid-to-powder conversion process
• A controlled-release composition
• A tablet or capsule containing a selected silica grade
• A manufacturing process using silica to improve content uniformity

These patents protect the drug product or manufacturing method, not necessarily the excipient as a standalone material.

Orange Book and Paragraph IV exposure

Hydrated silica itself is not an FDA-approved active pharmaceutical ingredient and is not ordinarily listed as an Orange Book drug product. It therefore does not have an Orange Book patent estate in the same sense as a branded active ingredient.

Paragraph IV litigation arises when a generic applicant challenges patents listed for a reference drug. A silica-containing formulation patent could become relevant to that litigation if it is properly listed and asserted, but the hydrated silica supplier would not automatically be the patent owner or litigation defendant.

When does hydrated silica lose exclusivity?

There is no single exclusivity expiration date for hydrated silica. The underlying material is a mature excipient. Commercial exclusivity is maintained through customer qualification, proprietary grades, manufacturing know-how, regulatory files, and application support.

A practical exclusivity framework is:

Protection type	Typical status
Basic amorphous silica composition	Generally mature and broadly available
Specific production process	May remain protected by patents or trade secrets
Specialized particle architecture	May have patent or know-how protection
Pharmaceutical grade and documentation	Protected commercially through qualification barriers
Drug-specific formulation	May be covered by product or method-of-use patents
Supplier quality system	Difficult to replicate quickly but not legal exclusivity

A pharmaceutical customer that changes silica suppliers may need to conduct comparability testing, update filings, assess process impact, and confirm stability. Those costs create switching friction even when the material itself is available from multiple producers.

How strong is the patent estate for hydrated silica?

The standalone patent estate is moderate to weak for commodity-grade hydrated silica and stronger for engineered, application-specific products.

Patent strength depends on four factors:

1. Whether the claims define measurable structural properties rather than broad material identity.
2. Whether the supplier can demonstrate a formulation benefit tied to those properties.
3. Whether alternative silica grades can avoid the claims.
4. Whether the claims cover a drug product with meaningful commercial value.

Process patents can be difficult to enforce because competing manufacturers may use different process conditions to produce similar performance. Drug-product patents can be stronger if they claim a narrow combination of active ingredient, silica characteristics, and performance outcome.

Trade secrets are important. Wet-process conditions, drying profiles, milling parameters, surface treatment, and quality-control methods may be difficult to reconstruct from the finished product.

What is the financial trajectory for hydrated silica suppliers?

The financial trajectory is likely to be steady rather than explosive. Pharmaceutical-grade demand can grow faster than commodity silica because of formulation outsourcing and higher-value applications, but it remains a small component of diversified producers’ revenue.

Revenue drivers

Revenue growth is supported by:

• Increased tablet and capsule production
• Demand for higher-performance excipients
• New formulations involving liquid or poorly soluble ingredients
• Oral-care volume
• Regional pharmaceutical manufacturing expansion
• Qualification of additional global sources
• Premium pricing for narrow particle and moisture specifications

Cost pressures

Margins are exposed to:

• Energy costs for precipitation, drying, and milling
• Sodium silicate and mineral feedstock costs
• Freight and packaging
• Environmental compliance
• Wastewater treatment
• Quality-control and regulatory documentation
• Capacity constraints for pharmaceutical-grade production

Suppliers with integrated manufacturing, multiple regional plants, and broad end-market exposure are better positioned to manage cyclical demand. Public companies generally do not disclose hydrated silica margins separately, so direct margin benchmarking is not possible.

Commercial outlook

Period	Expected market condition	Financial implication
Near term	Stable pharmaceutical demand with input-cost variability	Modest price increases where qualification barriers are high
Medium term	Growth in outsourced formulation and specialty oral dosage products	Better mix toward technical grades
Longer term	Greater demand for engineered carriers and application-specific excipients	Higher value per kilogram, but more validation costs

A key risk is substitution. Formulators may replace hydrated silica with colloidal silicon dioxide, magnesium aluminometasilicate, calcium silicate, microcrystalline cellulose blends, or other adsorbents when performance, cost, or regulatory precedent is better. Substitution is formulation-specific and usually requires development work.

What generic entry risks exist for silica-containing drugs?

Generic entry risk is determined by the drug product’s active ingredient patents, formulation patents, regulatory exclusivity, and the ease of reproducing the formulation.

Hydrated silica can affect generic development in several ways:

• A narrow formulation patent may claim a specific silica grade or ratio.
• The reference product may use a proprietary manufacturing process.
• A generic applicant may need to match dissolution, content uniformity, stability, and physical properties.
• The generic may avoid infringement by using another flow aid or carrier.
• The excipient supplier’s patent position may have little effect if the generic applicant uses a non-infringing alternative.

For conventional immediate-release tablets, excipient substitution is often technically feasible, although bioequivalence and manufacturing performance must still be demonstrated. For modified-release, amorphous-solid-dispersion, lipid-based, or highly specialized products, silica-related formulation claims can create more meaningful barriers.

What licensing deals and litigation affect hydrated silica?

No major publicly disclosed licensing transaction establishes a market-wide royalty or exclusivity benchmark for pharmaceutical hydrated silica. Commercial arrangements are more likely to involve supply agreements, quality agreements, technical-service contracts, and confidential development collaborations.

There is no general Orange Book litigation category for hydrated silica. Litigation risk usually arises indirectly through:

• Drug-product patent disputes
• Trade-secret claims involving silica manufacturing
• Contract disputes over supply or change control
• Product-liability claims involving contamination or specification failures
• Regulatory disputes concerning excipient identity or suitability

Public litigation searches should distinguish silica excipient disputes from crystalline-silica occupational cases, industrial antitrust claims, and patent litigation involving silica-containing drug formulations.

How does hydrated silica compare with colloidal silicon dioxide?

Attribute	Hydrated silica	Colloidal silicon dioxide
Typical production	Wet-process or precipitated routes	Often fumed or highly dispersed amorphous silica
Main pharmaceutical role	Adsorbent, carrier, flow aid	Glidant, anti-caking agent, flow enhancer
Moisture behavior	Often higher adsorption capacity	Strong flow improvement at low loading
Product differentiation	Pore structure, moisture, particle properties	Surface area, aggregate structure, dispersion
Substitution	Possible but formulation-specific	Possible but requires performance testing
Regulatory assessment	Grade-specific	Grade-specific
Patent position	Mature base material; specialized applications may be protected	Mature base material; engineered grades may be protected

The two materials should not be treated as interchangeable based only on the word “silica.” Flow, compaction, dissolution, blend uniformity, and stability can change materially after substitution.

What geographic factors shape the market?

North America and Europe remain important for high-documentation pharmaceutical grades. India and China are significant for pharmaceutical manufacturing growth and regional excipient demand. Asia-Pacific also has a wider supplier base and more price competition.

Geographic risks include:

• Single-region production
• Import and customs delays
• Different pharmacopoeial expectations
• Local registration requirements
• Energy-price volatility
• Environmental permitting
• Dependence on a single qualified plant

Pharmaceutical customers increasingly assess dual sourcing, but qualification of a second silica grade can require comparative testing and regulatory review. A supplier with plants in multiple regions has a commercial advantage even when its nominal product price is higher.

Key Takeaways

• Hydrated silica is a mature, specialized excipient with applications in powder flow, adsorption, carrier systems, and oral care.
• Public companies do not generally disclose pharmaceutical hydrated silica revenue separately.
• Growth is likely to be steady, supported by solid-dose manufacturing, CDMO activity, and higher-value engineered grades.
• The base material has limited standalone patent exclusivity.
• Commercial protection comes from grade performance, qualification history, regulatory documentation, manufacturing know-how, and customer switching costs.
• Hydrated silica has no standalone Orange Book exclusivity or Paragraph IV pathway.
• Generic risk arises through silica-containing drug-product patents, not through the excipient’s basic composition.
• The strongest financial opportunity is in validated pharmaceutical grades and application support, not commodity-volume expansion.
• Supplier comparison must be conducted at the individual grade level because hydrated silica, colloidal silicon dioxide, and fumed silica are not automatically interchangeable.

FAQs about hydrated silica excipient patents, suppliers, and market value

Is hydrated silica the same as colloidal silicon dioxide?

No. Both are amorphous silica materials, but they can differ in manufacturing process, particle structure, moisture content, surface area, and compendial identity. Substitution requires formulation and regulatory assessment.

Does hydrated silica require an FDA Drug Master File?

A Drug Master File can support regulatory review, but its use depends on the supplier’s regulatory strategy and the customer’s filing requirements. FDA’s Inactive Ingredient Database does not eliminate the need for product-specific qualification.

Can a generic manufacturer avoid a silica formulation patent?

Possibly. A generic applicant may use a different silica grade, a different excipient, or a different process if it can meet performance requirements and avoid the relevant patent claims.

Is pharmaceutical-grade hydrated silica more profitable than industrial silica?

It can generate higher value per kilogram because of qualification and documentation requirements. Profitability still depends on manufacturing scale, quality costs, utilization, and the supplier’s broader portfolio.

What is the main supply-chain risk for hydrated silica?

The main risk is loss of a qualified source or manufacturing change that affects particle properties, moisture, impurity levels, or formulation performance. Dual sourcing can reduce risk but usually requires comparability work.

References

1. European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia (11th ed.). Council of Europe.

2. European Food Safety Authority. (2017). Re-evaluation of silicon dioxide (E 551) as a food additive. EFSA Journal, 15(1), 4545. https://doi.org/10.2903/j.efsa.2017.4545

3. International Pharmaceutical Excipients Council. (2022). Good distribution practices guide for pharmaceutical excipients. IPEC Federation.

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (2024). Drug Master Files guidance for industry. https://www.fda.gov

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

7. Evonik Industries AG. (2024). Annual report 2024. Evonik Industries AG.

8. Solvay S.A. (2024). Annual integrated report 2024. Solvay S.A.